Lung Cancer Pill Cuts Risk of Death by Half, Study Finds - Slashdot

Do you develop on GitHub? You can keep using GitHub but automatically sync your GitHub releases to SourceForge quickly and easily with this tool so your projects have a backup location, and get your project in front of SourceForge's nearly 30 million monthly users. It takes less than a minute. Get new users downloading your project releases today!

Sign up for the Slashdot newsletter! or check out the new Slashdot job board to browse remote jobs or jobs in your area

The Guardian reports:

A pill taken once a day cuts the risk of dying from lung cancer by half, according to "thrilling" and "unprecedented" results from a decade-long global study. Taking the drug osimertinib after surgery dramatically reduced the risk of patients dying by 51%, results presented at the world's largest cancer conference showed...

Everyone in the trial had a mutation of the EGFR gene, which is found in about a quarter of global lung cancer cases, and accounts for as many as 40% of cases in Asia. An EGFR mutation is more common in women than men, and in people who have never smoked or have been light smokers. Speaking in Chicago, [Dr Roy Herbst, the deputy director of Yale Cancer Center and lead author of the study] said the "thrilling" results added huge weight to earlier findings from the same trial that showed the pill also halves the risk of a recurrence of the disease... Not everyone diagnosed with lung cancer is tested for the EGFR mutation, which needs to change, Herbst said, given the study's findings...

After five years, 88% of patients who took the daily pill after the removal of their tumour were still alive, compared with 78% of patients treated with a placebo. Overall, there was a 51% lower risk of death for those who received osimertinib compared with those who received placebo. The survival benefit "was observed consistently" in an analysis across all study subgroups, including those with stage one, stage two and stage three lung cancer. Chemotherapy had been given to 60% of those in the study, and the survival benefit of osimertinib was seen regardless of whether prior chemotherapy was received.

Do you have a GitHub project? Now you can sync your releases automatically with SourceForge and take advantage of both platforms.
Do you have a GitHub project? Now you can automatically sync your releases to SourceForge & take advantage of both platforms. The GitHub Import Tool allows you to quickly & easily import your GitHub project repos, releases, issues, & wiki to SourceForge with a few clicks. Then your future releases will be synced to SourceForge automatically. Your project will reach over 35 million more people per month and you’ll get detailed download statistics.
Sync Now